Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development

1. Second IPO Attempt: Artiva Biotherapeutics is attempting to go public for the second time, aiming to raise up to $135 million.
2. Funding for AlloNK: $55 million from the IPO will support the development of AlloNK, an NK cell therapy for systemic lupus erythematosus (SLE).
3. Share Pricing: Shares will be priced between $14 and $16 on the Nasdaq, with the company expecting to net a maximum of $135 million if underwriters exercise their options.
4. Pipeline Development: Remaining funds will support other programs in Artiva's pipeline and general purposes, with the IPO expected to fund the company through 2026.
5. Previous IPO Attempt: Artiva previously attempted an IPO in 2021 but halted plans to focus on a manufacturing and commercialization pact with Affimed.
6. Market Context: The biotech IPO market has seen an uptick, with 11 biotechs announcing IPO plans in the first half of 2024.